Non-Hodgkin Lymphoma clinical trials
Showing 101–143 of 143 active trials. Describe your situation to see which ones you may be eligible for.
- Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Global Cardio Oncology Registry
- Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
- Familial Investigations of Childhood Cancer Predisposition
- Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
- The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
- Tissue Collection for Studies of Lymph Cancer
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
- Family Study of Lymphoproliferative Disorders
- Lifestyle Intervention of Food and Exercise for Lymphoma Survivors
- Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
- UPLYFT For Lymphoma Survivors
- The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
- Improving Exercise Capacity With a Tailored Physical Activity Intervention
- Halt Aging in Survivors of Blood Cancers
- eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation
- GM-CSF With Post-Transplant Cyclophosphamide
- Vaccine Responses in Patients With B Cell Malignancies
- SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors
- Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
- BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies
- Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
- CD34+ Transplants for Leukemia and Lymphoma
- Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT
- Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation
- Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Photobiomodulation for Cancer-Related Cognitive Impairment
- Evaluation of Lymphoma Prognosis and Survivorship in Recently Diagnosed Patients, LEO Study
- Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
- Biology Studies of Hematologic Cancers
- A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
- Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)
- TmCD19-IL18 in CD19+ Cancers
- A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
- A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
- Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
- Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
- Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.